Clinical Advances in Hematology & Oncology : H&O
-
Publication Venue For
-
The Use of Zanubrutinib in Chronic Lymphocytic Leukemia.
20:1-4.
2022
-
The use of zanubrutinib in chronic lymphocytic leukemia..
20:705-708.
2022
-
How we manage grief..
20:561-563.
2022
-
Divide and Conquer, Cancer.
20:407.
2022
-
Systemic management of brain metastases in HER2+ breast cancer in 2022..
20:325-336.
2022
-
Update on metastatic hormone-sensitive prostate cancer..
20:277-280.
2022
-
Highlights in advanced prostate cancer from the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium: commentary..
20 Suppl 8:16-22.
2022
-
Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches..
20:227-238.
2022
-
The role of AR-V7 testing in the management of metastatic CRPC..
19:694-697.
2021
-
Highlights in advanced prostate cancer from the 2021 American Society of Clinical Oncology Annual Meeting: commentary..
19 Suppl 18:18-23.
2021
-
What's next for immunotherapy in locally advanced NSCLC?.
19:302-304.
2021
-
Highlights in Advanced Prostate Cancer From the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium: A Review of Selected Presentations From the All-Virtual Genitourinary Cancers Symposium February 11-13, 2021.
19.
2021
-
Highlights in advanced prostate cancer from the 2021 Genitourinary Cancers Symposium: commentary..
19 Suppl 15:20-23.
2021
-
The role of radiation treatment in metastatic prostate cancer..
18:707-709.
2020
-
Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma..
18:204-207.
2020
-
Prostate cancer in African American men..
18:154-156.
2020
-
Choosing the Best Approach for Patients With Favorable-Risk Metastatic Renal Cell Carcinoma Comment.
18:207-207.
2020
-
Becoming a surgeon-scientist: my transition from fellowship to faculty..
17:677-678.
2019
-
Caring for every patient, learning from every patient.
17:364.
2019
-
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy..
17:382-385.
2019
-
Outcomes.
17:258.
2019
-
Highlights in Advanced Prostate Cancer from the 2019 ASCO Genitourinary Cancers Symposium: Commentary..
17 Suppl 8:17-19.
2019
-
Talk to me.
17:142.
2019
-
Clinical advances: Past and present.
17:6.
2019
-
The use of multiparametric MRI in diagnosis and active surveillance of prostate cancer..
16:798-799.
2018
-
How we treat brain metastases in metastatic renal cell carcinoma..
16:110-114.
2018
-
Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer..
15:690-694.
2017
-
Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer..
15:184-188.
2017
-
Special concerns for survivors of prostate cancer..
14:674-676.
2016
-
Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss..
14:436-446.
2016
-
HER2 testing in metastatic colorectal cancer: ready for prime time?.
14:235-237.
2016
-
The future of kidney cancer treatment..
13:368-371.
2015
-
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer..
13:293-298.
2015
-
Is proton beam therapy better than standard radiation therapy? A paucity of practicality puts photons ahead of protons..
12:861-869.
2014
-
Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings.
12:18-21.
2014
-
Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings..
12:1-21.
2014
-
Heritable resistance to tyrosine kinase inhibitors..
12:454-457.
2014
-
CD30 diagnostics and testing.
12:9-15.
2014
-
Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy..
12:1-22.
2014
-
Highlights in advanced prostate cancer from the 2014 American Society of Clinical Oncology genitourinary cancers symposium: commentary..
12:12-16.
2014
-
Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?.
12:163-171.
2014
-
Biomarkers in castration-resistant prostate cancer.
12:115-118.
2014
-
Biomarkers in castration-resistant prostate cancer..
12:115-118.
2014
-
A paucity of practicality puts photons ahead of protons.
12:861-869.
2014
-
Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings.
12:18-21.
2014
-
Clinical phenotypes of castration-resistant prostate cancer..
11:707-718.
2013
-
Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary..
11 Suppl 14:16-22.
2013
-
Prevention and treatment of chemotherapy-induced neutropenia..
11:514-517.
2013
-
Recent advances in the management of castration-resistant prostate cancer..
11:181-183.
2013
-
Burkitt lymphoma: analysis of the genome..
10:54-55.
2012
-
The incidence of venous thromboembolism in cancer patients: a real-world analysis..
10:40-42.
2012
-
Clinical update: Epithelial-mesenchymal transition in cancer progression.
9:941-943.
2011
-
Epithelial-mesenchymal transition in cancer progression..
9:941-943.
2011
-
The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer..
9:1-14.
2011
-
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib..
9:734-745.
2011
-
Benefits and limitations of current treatment strategies in advanced prostate cancer.
9:3-5.
2011
-
Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer..
9:1-11.
2011
-
New and emerging treatments for advanced prostate cancer..
9:1-15.
2011
-
Prevention of venous thromboembolism in the non-surgical patient with cancer.
7:7-9.
2009
-
Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins..
7:54-64.
2009
-
Status of colon cancer vaccines. [An interview with Michael Morse by H&O]..
6:789-794.
2008
-
Second-line chemotherapy for advanced hormone-refractory prostate cancer..
6:118-132.
2008
-
Is radiation therapy required for patients with intermediate-risk rectal cancer?.
5:638-585.
2007
-
Male breast cancer during treatment with leuprolide for prostate cancer..
5:555-556.
2007
-
The role of targeted therapy in the treatment of colorectal cancer..
4:1-10.
2006
-
Pancreatoblastoma in a teenage patient..
4:150-153.
2006
-
Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions..
3:1-10.
2005
-
Radiotherapy for locally recurrent prostate cancer..
3:933-942.
2005
-
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX..
3:400-404.
2005
-
Novel therapeutic approaches to advanced prostate cancer..
3:271-282.
2005
-
Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy..
3:187-197.
2005
-
Highlights from the 46 th annual meeting of the American Society of Hematology..
3:111-116.
2005
-
The treatment of colorectal carcinoma: standard chemotherapy and beyond..
2:592-598.
2004
-
Aging and cancer..
2:457-465.
2004
-
Heparin-induced thrombocytopenia: clinical presentations and therapeutic management..
1:356-364.
2003
-
Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma..
1:99-100.
2003
-
The effects of cardiopulmonary bypass on coagulation..
11:589-591.
2013
-
Highlights in metastatic colorectal cancer from the American Society of Clinical Oncology Annual Meeting, June 3-7, 2011, Chicago, Illinois
2011
-
Prognostic factors in elderly patients with myelodysplastic syndrome or acute myeloid leukemia and the implications for treatment
2009
-
Highlights of the 2008 San Antonio Breast Cancer Symposium.
2009